1
|
Gardner LL, Thompson SJ, O'Connor JD, McMahon SJ. Modelling radiobiology. Phys Med Biol 2024; 69:18TR01. [PMID: 39159658 DOI: 10.1088/1361-6560/ad70f0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2024] [Accepted: 08/19/2024] [Indexed: 08/21/2024]
Abstract
Radiotherapy has played an essential role in cancer treatment for over a century, and remains one of the best-studied methods of cancer treatment. Because of its close links with the physical sciences, it has been the subject of extensive quantitative mathematical modelling, but a complete understanding of the mechanisms of radiotherapy has remained elusive. In part this is because of the complexity and range of scales involved in radiotherapy-from physical radiation interactions occurring over nanometres to evolution of patient responses over months and years. This review presents the current status and ongoing research in modelling radiotherapy responses across these scales, including basic physical mechanisms of DNA damage, the immediate biological responses this triggers, and genetic- and patient-level determinants of response. Finally, some of the major challenges in this field and potential avenues for future improvements are also discussed.
Collapse
Affiliation(s)
- Lydia L Gardner
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, United Kingdom
| | - Shannon J Thompson
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, United Kingdom
| | - John D O'Connor
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, United Kingdom
- Ulster University School of Engineering, York Street, Belfast BT15 1AP, United Kingdom
| | - Stephen J McMahon
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, United Kingdom
| |
Collapse
|
2
|
Hernández L, Estévez-Priego E, López-Pérez L, Fernanda Cabrera-Umpiérrez M, Arredondo MT, Fico G. HeNeCOn: An ontology for integrative research in Head and Neck cancer. Int J Med Inform 2024; 181:105284. [PMID: 37981440 DOI: 10.1016/j.ijmedinf.2023.105284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 07/14/2023] [Accepted: 11/01/2023] [Indexed: 11/21/2023]
Abstract
BACKGROUND Head and Neck Cancer (HNC) has a high incidence and prevalence in the worldwide population. The broad terminology associated with these diseases and their multimodality treatments generates large amounts of heterogeneous clinical data, which motivates the construction of a high-quality harmonization model to standardize this multi-source clinical data in terms of format and semantics. The use of ontologies and semantic techniques is a well-known approach to face this challenge. OBJECTIVE This work aims to provide a clinically reliable data model for HNC processes during all phases of the disease: prognosis, treatment, and follow-up. Therefore, we built the first ontology specifically focused on the HNC domain, named HeNeCOn (Head and Neck Cancer Ontology). METHODS First, an annotated dataset was established to provide a formal reference description of HNC. Then, 170 clinical variables were organized into a taxonomy, and later expanded and mapped to formalize and integrate multiple databases into the HeNeCOn ontology. The outcomes of this iterative process were reviewed and validated by clinicians and statisticians. RESULTS HeNeCOn is an ontology consisting of 502 classes, a taxonomy with a hierarchical structure, semantic definitions of 283 medical terms and detailed relations between them, which can be used as a tool for information extraction and knowledge management. CONCLUSION HeNeCOn is a reusable, extendible and standardized ontology which establishes a reference data model for terminology structure and standard definitions in the Head and Neck Cancer domain. This ontology allows handling both current and newly generated knowledge in Head and Neck cancer research, by means of data linking and mapping with other public ontologies.
Collapse
Affiliation(s)
- Liss Hernández
- Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, 28040 Madrid, Spain
| | - Estefanía Estévez-Priego
- Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, 28040 Madrid, Spain
| | - Laura López-Pérez
- Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, 28040 Madrid, Spain
| | | | - María Teresa Arredondo
- Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, 28040 Madrid, Spain
| | - Giuseppe Fico
- Universidad Politécnica de Madrid-Life Supporting Technologies Research Group, ETSIT, 28040 Madrid, Spain.
| |
Collapse
|
3
|
Field M, I Thwaites D, Carolan M, Delaney GP, Lehmann J, Sykes J, Vinod S, Holloway L. Infrastructure platform for privacy-preserving distributed machine learning development of computer-assisted theragnostics in cancer. J Biomed Inform 2022; 134:104181. [PMID: 36055639 DOI: 10.1016/j.jbi.2022.104181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 04/29/2022] [Accepted: 08/20/2022] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Emerging evidence suggests that data-driven support tools have found their way into clinical decision-making in a number of areas, including cancer care. Improving them and widening their scope of availability in various differing clinical scenarios, including for prognostic models derived from retrospective data, requires co-ordinated data sharing between clinical centres, secondary analyses of large multi-institutional clinical trial data, or distributed (federated) learning infrastructures. A systematic approach to utilizing routinely collected data across cancer care clinics remains a significant challenge due to privacy, administrative and political barriers. METHODS An information technology infrastructure and web service software was developed and implemented which uses machine learning to construct clinical decision support systems in a privacy-preserving manner across datasets geographically distributed in different hospitals. The infrastructure was deployed in a network of Australian hospitals. A harmonized, international ontology-linked, set of lung cancer databases were built with the routine clinical and imaging data at each centre. The infrastructure was demonstrated with the development of logistic regression models to predict major cardiovascular events following radiation therapy. RESULTS The infrastructure implemented forms the basis of the Australian computer-assisted theragnostics (AusCAT) network for radiation oncology data extraction, reporting and distributed learning. Four radiation oncology departments (across seven hospitals) in New South Wales (NSW) participated in this demonstration study. Infrastructure was deployed at each centre and used to develop a model predicting for cardiovascular admission within a year of receiving curative radiotherapy for non-small cell lung cancer. A total of 10417 lung cancer patients were identified with 802 being eligible for the model. Twenty features were chosen for analysis from the clinical record and linked registries. After selection, 8 features were included and a logistic regression model achieved an area under the receiver operating characteristic (AUROC) curve of 0.70 and C-index of 0.65 on out-of-sample data. CONCLUSION The infrastructure developed was demonstrated to be usable in practice between clinical centres to harmonize routinely collected oncology data and develop models with federated learning. It provides a promising approach to enable further research studies in radiation oncology using real world clinical data.
Collapse
Affiliation(s)
- Matthew Field
- South Western Sydney Clinical Campus, School of Clinical Medicine, University of New South Wales, NSW, Australia; South Western Sydney Cancer Services, NSW Health, Sydney, NSW, Australia; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
| | - David I Thwaites
- Institute of Medical Physics, School of Physics, University of Sydney, NSW, Australia
| | - Martin Carolan
- Illawarra Cancer Care Centre, Wollongong, NSW, Australia
| | - Geoff P Delaney
- South Western Sydney Clinical Campus, School of Clinical Medicine, University of New South Wales, NSW, Australia; South Western Sydney Cancer Services, NSW Health, Sydney, NSW, Australia; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia
| | - Joerg Lehmann
- Institute of Medical Physics, School of Physics, University of Sydney, NSW, Australia; Department of Radiation Oncology, Calvary Mater Newcastle, NSW, Australia
| | - Jonathan Sykes
- Institute of Medical Physics, School of Physics, University of Sydney, NSW, Australia; Blacktown Haematology and Oncology Cancer Care Centre, Blacktown Hospital, Blacktown, NSW, Australia; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia
| | - Shalini Vinod
- South Western Sydney Clinical Campus, School of Clinical Medicine, University of New South Wales, NSW, Australia; South Western Sydney Cancer Services, NSW Health, Sydney, NSW, Australia; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia
| | - Lois Holloway
- South Western Sydney Clinical Campus, School of Clinical Medicine, University of New South Wales, NSW, Australia; South Western Sydney Cancer Services, NSW Health, Sydney, NSW, Australia; Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia; Institute of Medical Physics, School of Physics, University of Sydney, NSW, Australia
| |
Collapse
|
4
|
Radiogenomics: A Valuable Tool for the Clinical Assessment and Research of Ovarian Cancer. J Comput Assist Tomogr 2022; 46:371-378. [DOI: 10.1097/rct.0000000000001279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Mali SA, Ibrahim A, Woodruff HC, Andrearczyk V, Müller H, Primakov S, Salahuddin Z, Chatterjee A, Lambin P. Making Radiomics More Reproducible across Scanner and Imaging Protocol Variations: A Review of Harmonization Methods. J Pers Med 2021; 11:842. [PMID: 34575619 PMCID: PMC8472571 DOI: 10.3390/jpm11090842] [Citation(s) in RCA: 68] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 08/21/2021] [Accepted: 08/24/2021] [Indexed: 12/13/2022] Open
Abstract
Radiomics converts medical images into mineable data via a high-throughput extraction of quantitative features used for clinical decision support. However, these radiomic features are susceptible to variation across scanners, acquisition protocols, and reconstruction settings. Various investigations have assessed the reproducibility and validation of radiomic features across these discrepancies. In this narrative review, we combine systematic keyword searches with prior domain knowledge to discuss various harmonization solutions to make the radiomic features more reproducible across various scanners and protocol settings. Different harmonization solutions are discussed and divided into two main categories: image domain and feature domain. The image domain category comprises methods such as the standardization of image acquisition, post-processing of raw sensor-level image data, data augmentation techniques, and style transfer. The feature domain category consists of methods such as the identification of reproducible features and normalization techniques such as statistical normalization, intensity harmonization, ComBat and its derivatives, and normalization using deep learning. We also reflect upon the importance of deep learning solutions for addressing variability across multi-centric radiomic studies especially using generative adversarial networks (GANs), neural style transfer (NST) techniques, or a combination of both. We cover a broader range of methods especially GANs and NST methods in more detail than previous reviews.
Collapse
Affiliation(s)
- Shruti Atul Mali
- The D-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands; (A.I.); (H.C.W.); (S.P.); (Z.S.); (A.C.); (P.L.)
| | - Abdalla Ibrahim
- The D-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands; (A.I.); (H.C.W.); (S.P.); (Z.S.); (A.C.); (P.L.)
- Department of Radiology and Nuclear Medicine, GROW—School for Oncology, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
- Department of Medical Physics, Division of Nuclear Medicine and Oncological Imaging, Hospital Center Universitaire de Liege, 4000 Liege, Belgium
- Department of Nuclear Medicine and Comprehensive Diagnostic Center Aachen (CDCA), University Hospital RWTH Aachen University, 52074 Aachen, Germany
| | - Henry C. Woodruff
- The D-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands; (A.I.); (H.C.W.); (S.P.); (Z.S.); (A.C.); (P.L.)
- Department of Radiology and Nuclear Medicine, GROW—School for Oncology, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
| | - Vincent Andrearczyk
- Institute of Information Systems, University of Applied Sciences and Arts Western Switzerland (HES-SO), rue du Technopole 3, 3960 Sierre, Switzerland; (V.A.); (H.M.)
| | - Henning Müller
- Institute of Information Systems, University of Applied Sciences and Arts Western Switzerland (HES-SO), rue du Technopole 3, 3960 Sierre, Switzerland; (V.A.); (H.M.)
| | - Sergey Primakov
- The D-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands; (A.I.); (H.C.W.); (S.P.); (Z.S.); (A.C.); (P.L.)
| | - Zohaib Salahuddin
- The D-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands; (A.I.); (H.C.W.); (S.P.); (Z.S.); (A.C.); (P.L.)
| | - Avishek Chatterjee
- The D-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands; (A.I.); (H.C.W.); (S.P.); (Z.S.); (A.C.); (P.L.)
| | - Philippe Lambin
- The D-Lab, Department of Precision Medicine, GROW—School for Oncology, Maastricht University, Maastricht, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands; (A.I.); (H.C.W.); (S.P.); (Z.S.); (A.C.); (P.L.)
- Department of Radiology and Nuclear Medicine, GROW—School for Oncology, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
| |
Collapse
|
6
|
Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix AN, Lambin P, Bottari F, Tsoutzidis N, Miraglio B, Walsh S, Vos W, Hustinx R, Ferreira M, Lovinfosse P, Leijenaar RTH. A review in radiomics: Making personalized medicine a reality via routine imaging. Med Res Rev 2021; 42:426-440. [PMID: 34309893 DOI: 10.1002/med.21846] [Citation(s) in RCA: 92] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 07/05/2021] [Accepted: 07/07/2021] [Indexed: 12/14/2022]
Abstract
Radiomics is the quantitative analysis of standard-of-care medical imaging; the information obtained can be applied within clinical decision support systems to create diagnostic, prognostic, and/or predictive models. Radiomics analysis can be performed by extracting hand-crafted radiomics features or via deep learning algorithms. Radiomics has evolved tremendously in the last decade, becoming a bridge between imaging and precision medicine. Radiomics exploits sophisticated image analysis tools coupled with statistical elaboration to extract the wealth of information hidden inside medical images, such as computed tomography (CT), magnetic resonance (MR), and/or Positron emission tomography (PET) scans, routinely performed in the everyday clinical practice. Many efforts have been devoted in recent years to the standardization and validation of radiomics approaches, to demonstrate their usefulness and robustness beyond any reasonable doubts. However, the booming of publications and commercial applications of radiomics approaches warrant caution and proper understanding of all the factors involved to avoid "scientific pollution" and overly enthusiastic claims by researchers and clinicians alike. For these reasons the present review aims to be a guidebook of sorts, describing the process of radiomics, its pitfalls, challenges, and opportunities, along with its ability to improve clinical decision-making, from oncology and respiratory medicine to pharmacological and genotyping studies.
Collapse
Affiliation(s)
- Julien Guiot
- Department of Pneumology, University Hospital of Liège, Liège, Belgium
| | - Akshayaa Vaidyanathan
- Radiomics (Oncoradiomics SA), Liège, Belgium.,The D-Lab, Department of Precision Medicine, Department of Nuclear Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands
| | - Louis Deprez
- Department of Radiology, University Hospital of Liège, Liège, Belgium
| | - Fadila Zerka
- Radiomics (Oncoradiomics SA), Liège, Belgium.,The D-Lab, Department of Precision Medicine, Department of Nuclear Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands
| | - Denis Danthine
- Department of Radiology, University Hospital of Liège, Liège, Belgium
| | - Anne-Noelle Frix
- Department of Pneumology, University Hospital of Liège, Liège, Belgium
| | - Philippe Lambin
- The D-Lab, Department of Precision Medicine, Department of Nuclear Medicine, GROW-School for Oncology, Maastricht University, Maastricht, The Netherlands
| | | | | | | | - Sean Walsh
- Radiomics (Oncoradiomics SA), Liège, Belgium
| | - Wim Vos
- Radiomics (Oncoradiomics SA), Liège, Belgium
| | - Roland Hustinx
- Department of Nuclear Medicine and Oncological Imaging, University Hospital of Liege, Liege, Belgium.,GIGA-CRC in vivo imaging, University of Liège, Liège, Belgium
| | - Marta Ferreira
- GIGA-CRC in vivo imaging, University of Liège, Liège, Belgium
| | - Pierre Lovinfosse
- Department of Nuclear Medicine and Oncological Imaging, University Hospital of Liege, Liege, Belgium
| | | |
Collapse
|
7
|
Ebert MA, Gulliford S, Acosta O, de Crevoisier R, McNutt T, Heemsbergen WD, Witte M, Palma G, Rancati T, Fiorino C. Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. Phys Med Biol 2021; 66:12TR01. [PMID: 34049304 DOI: 10.1088/1361-6560/ac0681] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 05/28/2021] [Indexed: 12/20/2022]
Abstract
For decades, dose-volume information for segmented anatomy has provided the essential data for correlating radiotherapy dosimetry with treatment-induced complications. Dose-volume information has formed the basis for modelling those associations via normal tissue complication probability (NTCP) models and for driving treatment planning. Limitations to this approach have been identified. Many studies have emerged demonstrating that the incorporation of information describing the spatial nature of the dose distribution, and potentially its correlation with anatomy, can provide more robust associations with toxicity and seed more general NTCP models. Such approaches are culminating in the application of computationally intensive processes such as machine learning and the application of neural networks. The opportunities these approaches have for individualising treatment, predicting toxicity and expanding the solution space for radiation therapy are substantial and have clearly widespread and disruptive potential. Impediments to reaching that potential include issues associated with data collection, model generalisation and validation. This review examines the role of spatial models of complication and summarises relevant published studies. Sources of data for these studies, appropriate statistical methodology frameworks for processing spatial dose information and extracting relevant features are described. Spatial complication modelling is consolidated as a pathway to guiding future developments towards effective, complication-free radiotherapy treatment.
Collapse
Affiliation(s)
- Martin A Ebert
- School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia
- Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
- 5D Clinics, Claremont, Western Australia, Australia
| | - Sarah Gulliford
- Department of Radiotherapy Physics, University College Hospitals London, United Kingdom
- Department of Medical Physics and Bioengineering, University College London, United Kingdom
| | - Oscar Acosta
- Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI-UMR 1099, F-35000 Rennes, France
| | | | - Todd McNutt
- Johns Hopkins University, Baltimore, Maryland, United States of America
| | | | - Marnix Witte
- The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Giuseppe Palma
- Institute of Biostructures and Bioimaging, National Research Council, Napoli, Italy
| | - Tiziana Rancati
- Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Claudio Fiorino
- Medical Physics, San Raffaele Scientific Institute, Milano, Italy
| |
Collapse
|
8
|
Chen Z, Xu L, Zhang C, Huang C, Wang M, Feng Z, Xiong Y. CT Radiomics Model for Discriminating the Risk Stratification of Gastrointestinal Stromal Tumors: A Multi-Class Classification and Multi-Center Study. Front Oncol 2021; 11:654114. [PMID: 34168985 PMCID: PMC8217748 DOI: 10.3389/fonc.2021.654114] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 05/11/2021] [Indexed: 12/16/2022] Open
Abstract
Objective To establish and verify a computed tomography (CT)-based multi-class prediction model for discriminating the risk stratification of gastrointestinal stromal tumors (GISTs). Materials and Methods A total of 381 patients with GISTs were confirmed by surgery and pathology. Information on 213 patients were obtained from one hospital and used as training cohort, whereas the details of 168 patients were collected from two other hospitals and used as independent validation cohort. Regions of interest on CT images of arterial and venous phases were drawn, radiomics features were extracted, and dimensionality reduction processing was performed. Using a one-vs-rest method, a Random Forest-based GISTs risk three-class prediction model was established, and the receiver operating characteristic curve (ROC) was used to evaluate the performance of the multi-class classification model, and the generalization ability was verified using external data. Results The training cohort included 96 very low-risk and low-risk, 60 intermediate-risk and 57 high-risk patients. External validation cohort included 82 very low-risk and low-risk, 48 intermediate-risk and 38 high-risk patients. The GISTs risk three-class radiomics model had a macro/micro average area under the curve (AUC) of 0.84 and an accuracy of 0.78 in the training cohort. It had a stable performance in the external validation cohort, with a macro/micro average AUC of 0.83 and an accuracy of 0.80. Conclusion CT radiomics can discriminate GISTs risk stratification. The performance of the three-class radiomics prediction model is good, and its generalization ability has also been verified in the external validation cohort, indicating its potential to assist stratified and accurate treatment of GISTs in the clinic.
Collapse
Affiliation(s)
- Zhonghua Chen
- Department of Radiology, Haining People's Hospital, Jiaxing, China
| | - Linyi Xu
- Department of Radiology, Haining People's Hospital, Jiaxing, China
| | - Chuanmin Zhang
- Department of Radiology, Haining People's Hospital, Jiaxing, China
| | - Chencui Huang
- Department of Research Collaboration, R&D Center, Beijing Deepwise & League of PHD Technology Co., Ltd, R&D Center, Beijing, China
| | - Minhong Wang
- Department of Radiology, First Affiliated Hospital of Wannan Medical College, Wuhu, China
| | - Zhan Feng
- Department of Radiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Yue Xiong
- Department of Radiology, Haining People's Hospital, Jiaxing, China
| |
Collapse
|
9
|
Prior F, Almeida J, Kathiravelu P, Kurc T, Smith K, Fitzgerald TJ, Saltz J. Open access image repositories: high-quality data to enable machine learning research. Clin Radiol 2020; 75:7-12. [PMID: 31040006 PMCID: PMC6815686 DOI: 10.1016/j.crad.2019.04.002] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 04/01/2019] [Indexed: 02/07/2023]
Abstract
Originally motivated by the need for research reproducibility and data reuse, large-scale, open access information repositories have become key resources for training and testing of advanced machine learning applications in biomedical and clinical research. To be of value, such repositories must provide large, high-quality data sets, where quality is defined as minimising variance due to data collection protocols and data misrepresentations. Curation is the key to quality. We have constructed a large public access image repository, The Cancer Imaging Archive, dedicated to the promotion of open science to advance the global effort to diagnose and treat cancer. Drawing on this experience and our experience in applying machine learning techniques to the analysis of radiology and pathology image data, we will review the requirements placed on such information repositories by state-of-the-art machine learning applications and how these requirements can be met.
Collapse
Affiliation(s)
- F Prior
- Department of Biomedical Informatics, University of Arkansas for Medical Sciences, 4301 W. Markham St, Little Rock, AR 72205, USA.
| | - J Almeida
- National Institutes of Health, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892, USA
| | - P Kathiravelu
- Department of Biomedical Informatics, Emory University, 101 Woodruff Circle, #4104, Atlanta, GA 30322, USA
| | - T Kurc
- Department of Biomedical Informatics, Stoney Brook University, Health Science Center Level 3, Room 043, Stony Brook, NY 11794, USA
| | - K Smith
- Department of Biomedical Informatics, University of Arkansas for Medical Sciences, 4301 W. Markham St, Little Rock, AR 72205, USA
| | - T J Fitzgerald
- Department of Radiation Oncology, University of Massachusetts Medical School, Worcester, MA 01655, USA
| | - J Saltz
- Department of Biomedical Informatics, Stoney Brook University, Health Science Center Level 3, Room 043, Stony Brook, NY 11794, USA
| |
Collapse
|
10
|
Kairn T, Crowe SB. Retrospective analysis of breast radiotherapy treatment plans: Curating the 'non-curated'. J Med Imaging Radiat Oncol 2019; 63:517-529. [PMID: 31081603 DOI: 10.1111/1754-9485.12892] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 03/24/2019] [Indexed: 11/29/2022]
Abstract
INTRODUCTION This paper provides a demonstration of how non-curated data can be retrospectively cleaned, so that existing repositories of radiotherapy treatment planning data can be used to complete bulk retrospective analyses of dosimetric trends and other plan characteristics. METHODS A non curated archive of 1137 radiotherapy treatment plans accumulated over a 12-month period, from five radiotherapy centres operated by one institution, was used to investigate and demonstrate a process of clinical data cleansing, by: identifying and translating inconsistent structure names; correcting inconsistent lung contouring; excluding plans for treatments other than breast tangents and plans without identifiable PTV, lung and heart structures; and identifying but not excluding plans that deviated from the local planning protocol. PTV, heart and lung dose-volume metrics were evaluated, in addition to a sample of personnel and linac load indicators. RESULTS Data cleansing reduced the number of treatment plans in the sample by 35.7%. Inconsistent structure names were successfully identified and translated (e.g. 35 different names for lung). Automatically separating whole lung structures into left and right lung structures allowed the effect of contralateral and ipsilateral lung dose to be evaluated, while introducing some small uncertainties, compared to manual contouring. PTV doses were indicative of prescription doses. Breast treatment work was unevenly distributed between oncologists and between metropolitan and regional centres. CONCLUSION This paper exemplifies the data cleansing and data analysis steps that may be completed using existing treatment planning data, to provide individual radiation oncology departments with access to information on their own patient populations. Clearly, the well-planned and systematic recording of new, high quality data is the preferred solution, but the retrospective curation of non-curated data may be a useful interim solution, for radiation oncology departments where the systems for recording of new data have yet to be designed and agreed.
Collapse
Affiliation(s)
- Tanya Kairn
- Genesis Cancer Care, Auchenflower, Queensland, Australia.,Science and Engineering Faculty, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Scott B Crowe
- Science and Engineering Faculty, Queensland University of Technology, Brisbane, Queensland, Australia.,Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
| |
Collapse
|
11
|
Mayo CS, Phillips M, McNutt TR, Palta J, Dekker A, Miller RC, Xiao Y, Moran JM, Matuszak MM, Gabriel P, Ayan AS, Prisciandaro J, Thor M, Dixit N, Popple R, Killoran J, Kaleba E, Kantor M, Ruan D, Kapoor R, Kessler ML, Lawrence TS. Treatment data and technical process challenges for practical big data efforts in radiation oncology. Med Phys 2018; 45:e793-e810. [PMID: 30226286 DOI: 10.1002/mp.13114] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 06/26/2018] [Accepted: 06/26/2018] [Indexed: 12/20/2022] Open
Abstract
The term Big Data has come to encompass a number of concepts and uses within medicine. This paper lays out the relevance and application of large collections of data in the radiation oncology community. We describe the potential importance and uses in clinical practice. The important concepts are then described and how they have been or could be implemented are discussed. Impediments to progress in the collection and use of sufficient quantities of data are also described. Finally, recommendations for how the community can move forward to achieve the potential of big data in radiation oncology are provided.
Collapse
Affiliation(s)
- C S Mayo
- University of Michigan, Ann Arbor, MI, USA
| | - M Phillips
- University of Washington, Seattle, WA, USA
| | - T R McNutt
- Johns Hopkins University, Baltimore, MD, USA
| | - J Palta
- Virginia Commonwealth University, Richmond, VA, USA
| | - A Dekker
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | | | - Y Xiao
- University of Pennsylvania, Philadelphia, PA, USA
| | - J M Moran
- University of Michigan, Ann Arbor, MI, USA
| | | | - P Gabriel
- University of Pennsylvania, Philadelphia, PA, USA
| | - A S Ayan
- Ohio State University, Columbus, OH, USA
| | | | - M Thor
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - N Dixit
- University of California at San Francisco, San Francisco, CA, USA
| | - R Popple
- University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - E Kaleba
- University of Michigan, Ann Arbor, MI, USA
| | - M Kantor
- MD Anderson Cancer Center, Houston, TX, USA
| | - D Ruan
- University of California at Los Angeles, Los Angeles, CA, USA
| | - R Kapoor
- Johns Hopkins University, Baltimore, MD, USA
| | | | | |
Collapse
|
12
|
Townend D. Conclusion: harmonisation in genomic and health data sharing for research: an impossible dream? Hum Genet 2018; 137:657-664. [PMID: 30120573 PMCID: PMC6132652 DOI: 10.1007/s00439-018-1924-x] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Accepted: 08/01/2018] [Indexed: 11/26/2022]
Abstract
There are clear benefits from genomics and health data sharing in research and in therapy for individuals across societies. At the same time, citizens have different expectations and fears about that data sharing. International legislation in relation with research ethics and practice and, particularly, data protection create a particular environment that, as is seen in the articles in part two of this special issue, are crying out for harmonisation both at a procedural but at fundamental conceptual levels. The law of data sharing is pulling in different directions. This paper poses the question, ‘harmonisation, an impossible dream?’ and the answer is a qualified ‘no’. The paper reflects on what can be seen in the papers in part two of the special issue. It then identifies three major areas of conceptual uncertainty in the new EU General Data Protection Regulation (not because it has superiority over other jurisdictions, but because it is a recent revision of data protection law that leaves universal conceptual questions unclear). Thereafter, the potential for Artificial Intelligence to meet some of the shortcomings is discussed. The paper ends with a consideration of the conditions under which data sharing harmonisation might be achieved: an understanding of a human rights approach and citizen sensitivities in considering the ‘public interest’; social liberalism as a basis of solidarity; and the profession of ‘researcher’.
Collapse
Affiliation(s)
- David Townend
- Department of Health, Ethics and Society, and CAPHRI (Care and Public Health Research Institute), Maastricht University, Maastricht, The Netherlands.
| |
Collapse
|
13
|
Anacleto A, Dias J. Data Analysis in Radiotherapy Treatments. INTERNATIONAL JOURNAL OF E-HEALTH AND MEDICAL COMMUNICATIONS 2018. [DOI: 10.4018/ijehmc.2018070103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Radiotherapy is one of the main cancer treatments available today, together with chemotherapy and surgery. Radiotherapy treatments have to be planned for each patient in an individualized manner. The knowledge acquired from one single treatment can be used to improve the treatment planning and outcome of several other patients. In the last years, attention has been drawn to the added value of using data analysis for radiotherapy treatment planning, prediction of treatment outcomes, survival analysis and quality assurance. In this article, existing literature is reviewed.
Collapse
Affiliation(s)
- Ana Anacleto
- Faculty of Economics, University of Coimbra, Coimbra, Portugal
| | - Joana Dias
- Inesc-Coimbra, CeBER, Faculty of Economics, University of Coimbra, Coimbra, Portugal
| |
Collapse
|
14
|
Thompson RF, Valdes G, Fuller CD, Carpenter CM, Morin O, Aneja S, Lindsay WD, Aerts HJWL, Agrimson B, Deville C, Rosenthal SA, Yu JB, Thomas CR. Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation? Radiother Oncol 2018; 129:421-426. [PMID: 29907338 DOI: 10.1016/j.radonc.2018.05.030] [Citation(s) in RCA: 131] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 05/29/2018] [Accepted: 05/30/2018] [Indexed: 12/16/2022]
Abstract
Artificial intelligence (AI) is emerging as a technology with the power to transform established industries, and with applications from automated manufacturing to advertising and facial recognition to fully autonomous transportation. Advances in each of these domains have led some to call AI the "fourth" industrial revolution [1]. In healthcare, AI is emerging as both a productive and disruptive force across many disciplines. This is perhaps most evident in Diagnostic Radiology and Pathology, specialties largely built around the processing and complex interpretation of medical images, where the role of AI is increasingly seen as both a boon and a threat. In Radiation Oncology as well, AI seems poised to reshape the specialty in significant ways, though the impact of AI has been relatively limited at present, and may rightly seem more distant to many, given the predominantly interpersonal and complex interventional nature of the specialty. In this overview, we will explore the current state and anticipated future impact of AI on Radiation Oncology, in detail, focusing on key topics from multiple stakeholder perspectives, as well as the role our specialty may play in helping to shape the future of AI within the larger spectrum of medicine.
Collapse
Affiliation(s)
- Reid F Thompson
- Oregon Health & Science University, Portland, USA; VA Portland Health Care System, Portland, USA.
| | - Gilmer Valdes
- University of California San Francisco, San Francisco, USA
| | | | | | - Olivier Morin
- University of California San Francisco, San Francisco, USA
| | | | | | - Hugo J W L Aerts
- Brigham and Women's Hospital, Boston, USA; Dana Farber Cancer Institute, Boston, USA
| | | | | | | | | | | |
Collapse
|
15
|
The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. Tech Innov Patient Support Radiat Oncol 2018; 7:11-16. [PMID: 32095576 PMCID: PMC7033755 DOI: 10.1016/j.tipsro.2018.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 04/24/2018] [Accepted: 05/10/2018] [Indexed: 11/22/2022] Open
Abstract
104 eligible lung cancer patients were approached, 86 (83%) consented to take part. At 1st attempt 69% of patients completed the ePRO questionnaire without assistance. Assistance was defined as verbal/physical help to complete the ePRO questionnaire. Most patients requiring help had a companion that could have provided assistance. More patients preferred electronic than paper questionnaires.
Background Treatment related toxicity is common after chemotherapy and radiotherapy. Our group has developed and validated an electronic Patient Reported Outcome questionnaire (ePRO) to assess symptoms and toxicity in lung cancer patients receiving (chemo)radiotherapy treatment. We assessed the need for volunteer support in clinics to assist patients in completing ePROs. Methods Lung Cancer patients attending outpatient or radiotherapy clinics at The Christie NHS Foundation Trust, Manchester were consented and asked to complete a Patient Reported Outcomes questionnaire using an electronic device (a touchscreen). Trained volunteers were available if patients required help such as verbal or physical assistance. The primary objective was to determine the need for volunteers to assist lung cancer patients in completing ePROs. Results 27/86 (31.4%) of patients who consented to this study required assistance to complete the ePRO. After questioning, we found that only 7/86 (8.1%) would have relied on volunteers for assistance as the majority of patients had a companion that could have provided help. 81/86 (94.2%) of patients were satisfied with the use of a touchscreen tablet to complete the ePRO. Conclusion Our results demonstrate that the introduction of ePROs in lung cancer outpatient clinics is feasible, even without the use of volunteers for the majority of patients. The implementation of ePROs would allow large volumes of high quality (chemo)radiotherapy toxicity data to be collected accurately and quickly. This is essential for the development of predictive models of outcome using population-based data, which could allow the personalisation of (chemo)radiotherapy treatment for lung cancer patients.
Collapse
|
16
|
Personalising Prostate Radiotherapy in the Era of Precision Medicine: A Review. J Med Imaging Radiat Sci 2018; 49:376-382. [PMID: 30514554 DOI: 10.1016/j.jmir.2018.01.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 12/27/2017] [Accepted: 01/18/2018] [Indexed: 12/14/2022]
Abstract
Prostate cancer continues to be the most commonly diagnosed cancer among Canadian men. The introduction of routine screening and advanced treatment options have allowed for a decrease in prostate cancer-related mortality, but outcomes following treatment continue to vary widely. In addition, the overtreatment of indolent prostate cancers causes unnecessary treatment toxicities and burdens health care systems. Accurate identification of patients who should undergo aggressive treatment, and those which should be managed more conservatively, needs to be implemented. More tumour and patient information is needed to stratify patients into low-, intermediate-, and high-risk groups to guide treatment options. This paper reviews the current literature on personalised prostate cancer management, including targeting tumour hypoxia, genomic and radiomic prognosticators, and radiobiological tumour targeting. A review of the current applications and future directions for the use of big data in radiation therapy is also presented. Prostate cancer management has a lot to gain from the implementation of personalised medicine into practice. Using specific tumour and patient characteristics to personalise prostate radiotherapy in the era of precision medicine will improve survival, decrease unnecessary toxicities, and minimise the heterogeneity of outcomes following treatment.
Collapse
|
17
|
Wu J, Tha KK, Xing L, Li R. Radiomics and radiogenomics for precision radiotherapy. JOURNAL OF RADIATION RESEARCH 2018; 59:i25-i31. [PMID: 29385618 PMCID: PMC5868194 DOI: 10.1093/jrr/rrx102] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Revised: 12/14/2017] [Indexed: 06/07/2023]
Abstract
Imaging plays an important role in the diagnosis and staging of cancer, as well as in radiation treatment planning and evaluation of therapeutic response. Recently, there has been significant interest in extracting quantitative information from clinical standard-of-care images, i.e. radiomics, in order to provide a more comprehensive characterization of image phenotypes of the tumor. A number of studies have demonstrated that a deeper radiomic analysis can reveal novel image features that could provide useful diagnostic, prognostic or predictive information, improving upon currently used imaging metrics such as tumor size and volume. Furthermore, these imaging-derived phenotypes can be linked with genomic data, i.e. radiogenomics, in order to understand their biological underpinnings or further improve the prediction accuracy of clinical outcomes. In this article, we will provide an overview of radiomics and radiogenomics, including their rationale, technical and clinical aspects. We will also present some examples of the current results and some emerging paradigms in radiomics and radiogenomics for clinical oncology, with a focus on potential applications in radiotherapy. Finally, we will highlight the challenges in the field and suggest possible future directions in radiomics to maximize its potential impact on precision radiotherapy.
Collapse
Affiliation(s)
- Jia Wu
- Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5847, USA
| | - Khin Khin Tha
- Global Station for Quantum Biomedical Science and Engineering, Global Institute for Cooperative Research and Education, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan
| | - Lei Xing
- Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5847, USA
- Global Station for Quantum Biomedical Science and Engineering, Global Institute for Cooperative Research and Education, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan
| | - Ruijiang Li
- Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5847, USA
- Global Station for Quantum Biomedical Science and Engineering, Global Institute for Cooperative Research and Education, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan
| |
Collapse
|
18
|
Whitaker TJ, Mayo CS, Ma DJ, Haddock MG, Miller RC, Corbin KS, Neben-Wittich M, Leenstra JL, Laack NN, Fatyga M, Schild SE, Vargas CE, Tzou KS, Hadley AR, Buskirk SJ, Foote RL. Data collection of patient outcomes: one institution's experience. JOURNAL OF RADIATION RESEARCH 2018. [PMID: 29538757 PMCID: PMC5868196 DOI: 10.1093/jrr/rry013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
Patient- and provider-reported outcomes are recognized as important in evaluating quality of care, guiding health care policy, comparative effectiveness research, and decision-making in radiation oncology. Combining patient and provider outcome data with a detailed description of disease and therapy is the basis for these analyses. We report on the combination of technical solutions and clinical process changes at our institution that were used in the collection and dissemination of this data. This initiative has resulted in the collection of treatment data for 23 541 patients, 20 465 patients with provider-based adverse event records, and patient-reported outcome surveys submitted by 5622 patients. All of the data is made accessible using a self-service web-based tool.
Collapse
Affiliation(s)
- Thomas J Whitaker
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
- Corresponding author. Department of Radiation Oncology, Mayo Clinic, 200 First St. S.W., Rochester, MN, USA. Tel: +01-507-255-2129; Fax: +01-507-284-0079;
| | - Charles S Mayo
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA
| | - Daniel J Ma
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Michael G Haddock
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Robert C Miller
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | - Kimberly S Corbin
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | | | - James L Leenstra
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Nadia N Laack
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Mirek Fatyga
- Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA
| | - Steven E Schild
- Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA
| | - Carlos E Vargas
- Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA
| | - Katherine S Tzou
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | - Austin R Hadley
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | - Steven J Buskirk
- Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA
| | - Robert L Foote
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
19
|
Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability. Cancers (Basel) 2018; 10:cancers10020055. [PMID: 29463018 PMCID: PMC5836087 DOI: 10.3390/cancers10020055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2017] [Revised: 01/19/2018] [Accepted: 02/14/2018] [Indexed: 12/25/2022] Open
Abstract
We present a methodology which can be utilized to select proton or photon radiotherapy in prostate cancer patients. Four state-of-the-art competing treatment modalities were compared (by way of an in silico trial) for a cohort of 25 prostate cancer patients, with and without correction strategies for prostate displacements. Metrics measured from clinical image guidance systems were used. Three correction strategies were investigated; no-correction, extended-no-action-limit, and online-correction. Clinical efficacy was estimated via radiobiological models incorporating robustness (how probable a given treatment plan was delivered) and stability (the consistency between the probable best and worst delivered treatments at the 95% confidence limit). The results obtained at the cohort level enabled the determination of a threshold for likely clinical benefit at the individual level. Depending on the imaging system and correction strategy; 24%, 32% and 44% of patients were identified as suitable candidates for proton therapy. For the constraints of this study: Intensity-modulated proton therapy with online-correction was on average the most effective modality. Irrespective of the imaging system, each treatment modality is similar in terms of robustness, with and without the correction strategies. Conversely, there is substantial variation in stability between the treatment modalities, which is greatly reduced by correction strategies. This study provides a ‘proof-of-concept’ methodology to enable the prospective identification of individual patients that will most likely (above a certain threshold) benefit from proton therapy.
Collapse
|
20
|
Les big data , généralités et intégration en radiothérapie. Cancer Radiother 2018; 22:73-84. [DOI: 10.1016/j.canrad.2017.04.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 04/11/2017] [Accepted: 04/19/2017] [Indexed: 12/25/2022]
|
21
|
Bibault JE, Zapletal E, Rance B, Giraud P, Burgun A. Labeling for Big Data in radiation oncology: The Radiation Oncology Structures ontology. PLoS One 2018; 13:e0191263. [PMID: 29351341 PMCID: PMC5774757 DOI: 10.1371/journal.pone.0191263] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Accepted: 01/01/2018] [Indexed: 12/25/2022] Open
Abstract
Purpose Leveraging Electronic Health Records (EHR) and Oncology Information Systems (OIS) has great potential to generate hypotheses for cancer treatment, since they directly provide medical data on a large scale. In order to gather a significant amount of patients with a high level of clinical details, multicenter studies are necessary. A challenge in creating high quality Big Data studies involving several treatment centers is the lack of semantic interoperability between data sources. We present the ontology we developed to address this issue. Methods Radiation Oncology anatomical and target volumes were categorized in anatomical and treatment planning classes. International delineation guidelines specific to radiation oncology were used for lymph nodes areas and target volumes. Hierarchical classes were created to generate The Radiation Oncology Structures (ROS) Ontology. The ROS was then applied to the data from our institution. Results Four hundred and seventeen classes were created with a maximum of 14 children classes (average = 5). The ontology was then converted into a Web Ontology Language (.owl) format and made available online on Bioportal and GitHub under an Apache 2.0 License. We extracted all structures delineated in our department since the opening in 2001. 20,758 structures were exported from our “record-and-verify” system, demonstrating a significant heterogeneity within a single center. All structures were matched to the ROS ontology before integration into our clinical data warehouse (CDW). Conclusion In this study we describe a new ontology, specific to radiation oncology, that reports all anatomical and treatment planning structures that can be delineated. This ontology will be used to integrate dosimetric data in the Assistance Publique—Hôpitaux de Paris CDW that stores data from 6.5 million patients (as of February 2017).
Collapse
Affiliation(s)
- Jean-Emmanuel Bibault
- Radiation Oncology Department, Georges Pompidou European Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris Sorbonne Cité, Paris, France
- INSERM UMR 1138 Team 22: Information Sciences to support Personalized Medicine, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- * E-mail:
| | - Eric Zapletal
- Biomedical Informatics and Public Health Department, Georges Pompidou European Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris Sorbonne Cité, Paris, France
| | - Bastien Rance
- INSERM UMR 1138 Team 22: Information Sciences to support Personalized Medicine, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- Biomedical Informatics and Public Health Department, Georges Pompidou European Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris Sorbonne Cité, Paris, France
| | - Philippe Giraud
- Radiation Oncology Department, Georges Pompidou European Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris Sorbonne Cité, Paris, France
| | - Anita Burgun
- INSERM UMR 1138 Team 22: Information Sciences to support Personalized Medicine, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- Biomedical Informatics and Public Health Department, Georges Pompidou European Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris Sorbonne Cité, Paris, France
| |
Collapse
|
22
|
Brink C, Lorenzen EL, Krogh SL, Westberg J, Berg M, Jensen I, Thomsen MS, Yates ES, Offersen BV. DBCG hypo trial validation of radiotherapy parameters from a national data bank versus manual reporting. Acta Oncol 2018; 57:107-112. [PMID: 29202666 DOI: 10.1080/0284186x.2017.1406140] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
INTRODUCTION The current study evaluates the data quality achievable using a national data bank for reporting radiotherapy parameters relative to the classical manual reporting method of selected parameters. METHODS The data comparison is based on 1522 Danish patients of the DBCG hypo trial with data stored in the Danish national radiotherapy data bank. In line with standard DBCG trial practice selected parameters were also reported manually to the DBCG database. Categorical variables are compared using contingency tables, and comparison of continuous parameters is presented in scatter plots. RESULTS For categorical variables 25 differences between the data bank and manual values were located. Of these 23 were related to mistakes in the manual reported value whilst the remaining two were a wrong classification in the data bank. The wrong classification in the data bank was related to lack of dose information, since the two patients had been treated with an electron boost based on a manual calculation, thus data was not exported to the data bank, and this was not detected prior to comparison with the manual data. For a few database fields in the manual data an ambiguity of the parameter definition of the specific field is seen in the data. This was not the case for the data bank, which extract all data consistently. CONCLUSIONS In terms of data quality the data bank is superior to manually reported values. However, there is a need to allocate resources for checking the validity of the available data as well as ensuring that all relevant data is present. The data bank contains more detailed information, and thus facilitates research related to the actual dose distribution in the patients.
Collapse
Affiliation(s)
- Carsten Brink
- Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
- Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark
| | - Ebbe L. Lorenzen
- Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark
| | - Simon Long Krogh
- Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark
| | - Jonas Westberg
- Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark
| | - Martin Berg
- Department of Medical Physics, Vejle Hospital, Vejle, Denmark
| | - Ingelise Jensen
- Department of Medical Physics, Aalborg University Hospital, Aalborg, Denmark
| | | | | | - Birgitte Vrou Offersen
- Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| |
Collapse
|
23
|
Mattiucci GC, Cellini F. Role of the modern radiotherapy in the postoperative setting for esophageal cancer. J Thorac Dis 2017; 9:4212-4215. [PMID: 29268474 DOI: 10.21037/jtd.2017.10.07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Gian-Carlo Mattiucci
- Gemelli ART, Radiation Oncology Department, Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy
| | - Francesco Cellini
- Gemelli ART, Radiation Oncology Department, Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy
| |
Collapse
|
24
|
Benedict SH, Hoffman K, Martel MK, Abernethy AP, Asher AL, Capala J, Chen RC, Chera B, Couch J, Deye J, Efstathiou JA, Ford E, Fraass BA, Gabriel PE, Huser V, Kavanagh BD, Khuntia D, Marks LB, Mayo C, McNutt T, Miller RS, Moore KL, Prior F, Roelofs E, Rosenstein BS, Sloan J, Theriault A, Vikram B. Overview of the American Society for Radiation Oncology-National Institutes of Health-American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. Int J Radiat Oncol Biol Phys 2017; 95:873-879. [PMID: 27302503 DOI: 10.1016/j.ijrobp.2016.03.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2016] [Revised: 03/03/2016] [Accepted: 03/08/2016] [Indexed: 01/24/2023]
Affiliation(s)
| | - Karen Hoffman
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Mary K Martel
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | - Anthony L Asher
- American Association of Neurological Surgeons, Rolling Meadows, Illinois
| | - Jacek Capala
- Clinical Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Ronald C Chen
- University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - Bhisham Chera
- University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - Jennifer Couch
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - James Deye
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Jason A Efstathiou
- Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Eric Ford
- University of Washington, Seattle, Washington
| | | | - Peter E Gabriel
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Vojtech Huser
- Lister Hill National Center for Biomedical Communications, National Library of Medicine, National Institutes of Health, Bethesda, Maryland
| | | | | | - Lawrence B Marks
- University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | | | - Todd McNutt
- The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Kevin L Moore
- University of California, San Diego, La Jolla, California
| | - Fred Prior
- University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Erik Roelofs
- Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands
| | | | | | | | - Bhadrasain Vikram
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| |
Collapse
|
25
|
Abstract
Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research. Radiomic analysis exploits sophisticated image analysis tools and the rapid development and validation of medical imaging data that uses image-based signatures for precision diagnosis and treatment, providing a powerful tool in modern medicine. Herein, we describe the process of radiomics, its pitfalls, challenges, opportunities, and its capacity to improve clinical decision making, emphasizing the utility for patients with cancer. Currently, the field of radiomics lacks standardized evaluation of both the scientific integrity and the clinical relevance of the numerous published radiomics investigations resulting from the rapid growth of this area. Rigorous evaluation criteria and reporting guidelines need to be established in order for radiomics to mature as a discipline. Herein, we provide guidance for investigations to meet this urgent need in the field of radiomics.
Collapse
|
26
|
Chennubhotla C, Clarke LP, Fedorov A, Foran D, Harris G, Helton E, Nordstrom R, Prior F, Rubin D, Saltz JH, Shalley E, Sharma A. An Assessment of Imaging Informatics for Precision Medicine in Cancer. Yearb Med Inform 2017; 26:110-119. [PMID: 29063549 DOI: 10.15265/iy-2017-041] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Objectives: Precision medicine requires the measurement, quantification, and cataloging of medical characteristics to identify the most effective medical intervention. However, the amount of available data exceeds our current capacity to extract meaningful information. We examine the informatics needs to achieve precision medicine from the perspective of quantitative imaging and oncology. Methods: The National Cancer Institute (NCI) organized several workshops on the topic of medical imaging and precision medicine. The observations and recommendations are summarized herein. Results: Recommendations include: use of standards in data collection and clinical correlates to promote interoperability; data sharing and validation of imaging tools; clinician's feedback in all phases of research and development; use of open-source architecture to encourage reproducibility and reusability; use of challenges which simulate real-world situations to incentivize innovation; partnership with industry to facilitate commercialization; and education in academic communities regarding the challenges involved with translation of technology from the research domain to clinical utility and the benefits of doing so. Conclusions: This article provides a survey of the role and priorities for imaging informatics to help advance quantitative imaging in the era of precision medicine. While these recommendations were drawn from oncology, they are relevant and applicable to other clinical domains where imaging aids precision medicine.
Collapse
|
27
|
Roberts K, Boland MR, Pruinelli L, Dcruz J, Berry A, Georgsson M, Hazen R, Sarmiento RF, Backonja U, Yu KH, Jiang Y, Brennan PF. Biomedical informatics advancing the national health agenda: the AMIA 2015 year-in-review in clinical and consumer informatics. J Am Med Inform Assoc 2017; 24:e185-e190. [PMID: 27497798 PMCID: PMC6080724 DOI: 10.1093/jamia/ocw103] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 05/13/2016] [Accepted: 05/22/2016] [Indexed: 12/24/2022] Open
Abstract
The field of biomedical informatics experienced a productive 2015 in terms of research. In order to highlight the accomplishments of that research, elicit trends, and identify shortcomings at a macro level, a 19-person team conducted an extensive review of the literature in clinical and consumer informatics. The result of this process included a year-in-review presentation at the American Medical Informatics Association Annual Symposium and a written report (see supplemental data). Key findings are detailed in the report and summarized here. This article organizes the clinical and consumer health informatics research from 2015 under 3 themes: the electronic health record (EHR), the learning health system (LHS), and consumer engagement. Key findings include the following: (1) There are significant advances in establishing policies for EHR feature implementation, but increased interoperability is necessary for these to gain traction. (2) Decision support systems improve practice behaviors, but evidence of their impact on clinical outcomes is still lacking. (3) Progress in natural language processing (NLP) suggests that we are approaching but have not yet achieved truly interactive NLP systems. (4) Prediction models are becoming more robust but remain hampered by the lack of interoperable clinical data records. (5) Consumers can and will use mobile applications for improved engagement, yet EHR integration remains elusive.
Collapse
Affiliation(s)
- Kirk Roberts
- US National Library of Medicine, Bethesda, Maryland
- School of Biomedical Informatics, University of Texas Health Science Center at Houston
| | | | | | - Jina Dcruz
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Andrew Berry
- Department of Human Centered Design and Engineering, University of Washington, Seattle
| | - Mattias Georgsson
- Department of Applied Health Technology, Blekinge Institute of Technology, Blekinge, Sweden
| | - Rebecca Hazen
- Department of Biomedical and Health Informatics, University of Washington
| | | | - Uba Backonja
- Department of Biomedical and Health Informatics, University of Washington
| | - Kun-Hsing Yu
- Department of Biomedical Informatics, Stanford University School of Medicine, Stanford, California
| | - Yun Jiang
- Department of Systems, Population, and Leadership, University of Michigan School of Nursing, Ann Arbor
| | | |
Collapse
|
28
|
Lambin P, Zindler J, Vanneste BGL, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RTHM, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EEC, Even AJG, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RTH, Zegers CML, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev 2017; 109:131-153. [PMID: 26774327 DOI: 10.1016/j.addr.2016.01.006] [Citation(s) in RCA: 81] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Revised: 12/08/2015] [Accepted: 01/06/2016] [Indexed: 12/12/2022]
Abstract
A paradigm shift from current population based medicine to personalized and participative medicine is underway. This transition is being supported by the development of clinical decision support systems based on prediction models of treatment outcome. In radiation oncology, these models 'learn' using advanced and innovative information technologies (ideally in a distributed fashion - please watch the animation: http://youtu.be/ZDJFOxpwqEA) from all available/appropriate medical data (clinical, treatment, imaging, biological/genetic, etc.) to achieve the highest possible accuracy with respect to prediction of tumor response and normal tissue toxicity. In this position paper, we deliver an overview of the factors that are associated with outcome in radiation oncology and discuss the methodology behind the development of accurate prediction models, which is a multi-faceted process. Subsequent to initial development/validation and clinical introduction, decision support systems should be constantly re-evaluated (through quality assurance procedures) in different patient datasets in order to refine and re-optimize the models, ensuring the continuous utility of the models. In the reasonably near future, decision support systems will be fully integrated within the clinic, with data and knowledge being shared in a standardized, dynamic, and potentially global manner enabling truly personalized and participative medicine.
Collapse
Affiliation(s)
- Philippe Lambin
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
| | - Jaap Zindler
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Ben G L Vanneste
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Lien Van De Voorde
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Daniëlle Eekers
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Inge Compter
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Kranthi Marella Panth
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Jurgen Peerlings
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Ruben T H M Larue
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Timo M Deist
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Arthur Jochems
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Tim Lustberg
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Johan van Soest
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Evelyn E C de Jong
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Aniek J G Even
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Bart Reymen
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Nicolle Rekers
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Marike van Gisbergen
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Erik Roelofs
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Sara Carvalho
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Ralph T H Leijenaar
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Catharina M L Zegers
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Maria Jacobs
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Janita van Timmeren
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Patricia Brouwers
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Jonathan A Lal
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Ludwig Dubois
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Ala Yaromina
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Evert Jan Van Limbergen
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Maaike Berbee
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Wouter van Elmpt
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Cary Oberije
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Bram Ramaekers
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Andre Dekker
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Liesbeth J Boersma
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Frank Hoebers
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Kim M Smits
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Adriana J Berlanga
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Sean Walsh
- Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
| |
Collapse
|
29
|
Tabatabaei MS, Langarizadeh M, Tavakol K. An Evaluation Protocol for Picture Archiving and Communication System: a Systematic Review. Acta Inform Med 2017; 25:250-253. [PMID: 29284915 PMCID: PMC5723173 DOI: 10.5455/aim.2017.25.250-253] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Introduction: Picture archiving and communication system (PACS) serves to store, transmit, communicate and manage medical images. A logical evaluation protocol assists to determine whether the system is technically, structurally and operationally fit. The purpose of this systematic review was to propose a logical evaluation protocol for PACS, particularly useful for new hospitals and other healthcare institutions in developing countries. Methods and Materials: We systematically reviewed 25 out of 267 full-length articles, published between 2000 and 2017, retrieved from four sources: Science Direct, Scopus, PubMed and Google Scholar. The extracted data were tabulated and reviewed successively by three independent panels of experts that oversaw the design of this study and the process by which the PACS evaluation protocol was systematically developed. Results: The outcome data were ranked by expert panels and analyzed statistically, with the reliability established at 0.82 based on the Pearson’s correlation coefficient. The essential components and the best options to establish an optimal PACS were organized under nine main sections: system configuration;system network;data storage; datacompression;image input; image characteristics; image presentation; communication link; and system security, with a total of 20 components, each of which capable of working optimally with one or more program options. Conclusions: This systematic review presents an objective protocol that is an ideal tool for the evaluation of new or existing PACS at healthcare institutions, particularly in developing countries. Despite the significant advantages, the protocol may face minor limitations, largely due to lack of appropriate technical resources in various clinical settings and the host countries.
Collapse
Affiliation(s)
- Mohsen S Tabatabaei
- Department of Health Information Management, School of Health Management and Information Sciences, Iran University of Medical Sciences. Tehran, Iran
| | - Mostafa Langarizadeh
- Department of Health Information Management, School of Health Management and Information Sciences, Iran University of Medical Sciences. Tehran, Iran
| | - Kamran Tavakol
- School of Medicine, University of Maryland Baltimore. Baltimore, MD, USA
| |
Collapse
|
30
|
Distributed learning: Developing a predictive model based on data from multiple hospitals without data leaving the hospital – A real life proof of concept. Radiother Oncol 2016; 121:459-467. [DOI: 10.1016/j.radonc.2016.10.002] [Citation(s) in RCA: 113] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Revised: 08/25/2016] [Accepted: 10/03/2016] [Indexed: 12/22/2022]
|
31
|
Mayo CS, Kessler ML, Eisbruch A, Weyburne G, Feng M, Hayman JA, Jolly S, El Naqa I, Moran JM, Matuszak MM, Anderson CJ, Holevinski LP, McShan DL, Merkel SM, Machnak SL, Lawrence TS, Ten Haken RK. The big data effort in radiation oncology: Data mining or data farming? Adv Radiat Oncol 2016; 1:260-271. [PMID: 28740896 PMCID: PMC5514231 DOI: 10.1016/j.adro.2016.10.001] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Revised: 09/23/2016] [Accepted: 10/05/2016] [Indexed: 12/01/2022] Open
Abstract
Although large volumes of information are entered into our electronic health care records, radiation oncology information systems and treatment planning systems on a daily basis, the goal of extracting and using this big data has been slow to emerge. Development of strategies to meet this goal is aided by examining issues with a data farming instead of a data mining conceptualization. Using this model, a vision of key data elements, clinical process changes, technology issues and solutions, and role for professional societies is presented. With a better view of technology, process and standardization factors, definition and prioritization of efforts can be more effectively directed.
Collapse
Affiliation(s)
- Charles S Mayo
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Marc L Kessler
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Avraham Eisbruch
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Grant Weyburne
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Mary Feng
- Department of Radiation Oncology, University of California at San Francisco, San Francisco, California
| | - James A Hayman
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Shruti Jolly
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Issam El Naqa
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Jean M Moran
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Martha M Matuszak
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Carlos J Anderson
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Lynn P Holevinski
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Daniel L McShan
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Sue M Merkel
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Sherry L Machnak
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Theodore S Lawrence
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Randall K Ten Haken
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| |
Collapse
|
32
|
Skripcak T, Just U, Simon M, Buttner D, Luhr A, Baumann M, Krause M. Toward Distributed Conduction of Large-Scale Studies in Radiation Therapy and Oncology: Open-Source System Integration Approach. IEEE J Biomed Health Inform 2016. [DOI: 10.1109/jbhi.2015.2450833] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
33
|
Tagliaferri L, Kovács G, Autorino R, Budrukkar A, Guinot JL, Hildebrand G, Johansson B, Monge RM, Meyer JE, Niehoff P, Rovirosa A, Takàcsi-Nagy Z, Dinapoli N, Lanzotti V, Damiani A, Soror T, Valentini V. ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy 2016; 8:336-43. [PMID: 27648088 PMCID: PMC5018530 DOI: 10.5114/jcb.2016.61958] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 07/28/2016] [Indexed: 12/27/2022] Open
Abstract
PURPOSE Aim of the COBRA (Consortium for Brachytherapy Data Analysis) project is to create a multicenter group (consortium) and a web-based system for standardized data collection. MATERIAL AND METHODS GEC-ESTRO (Groupe Européen de Curiethérapie - European Society for Radiotherapy & Oncology) Head and Neck (H&N) Working Group participated in the project and in the implementation of the consortium agreement, the ontology (data-set) and the necessary COBRA software services as well as the peer reviewing of the general anatomic site-specific COBRA protocol. The ontology was defined by a multicenter task-group. RESULTS Eleven centers from 6 countries signed an agreement and the consortium approved the ontology. We identified 3 tiers for the data set: Registry (epidemiology analysis), Procedures (prediction models and DSS), and Research (radiomics). The COBRA-Storage System (C-SS) is not time-consuming as, thanks to the use of "brokers", data can be extracted directly from the single center's storage systems through a connection with "structured query language database" (SQL-DB), Microsoft Access(®), FileMaker Pro(®), or Microsoft Excel(®). The system is also structured to perform automatic archiving directly from the treatment planning system or afterloading machine. The architecture is based on the concept of "on-purpose data projection". The C-SS architecture is privacy protecting because it will never make visible data that could identify an individual patient. This C-SS can also benefit from the so called "distributed learning" approaches, in which data never leave the collecting institution, while learning algorithms and proposed predictive models are commonly shared. CONCLUSIONS Setting up a consortium is a feasible and practicable tool in the creation of an international and multi-system data sharing system. COBRA C-SS seems to be well accepted by all involved parties, primarily because it does not influence the center's own data storing technologies, procedures, and habits. Furthermore, the method preserves the privacy of all patients.
Collapse
Affiliation(s)
- Luca Tagliaferri
- Department of Radiation Oncology – Gemelli-ART, Catholic University, Italy
| | - György Kovács
- Interdisciplinary Brachytherapy Unit, University of Lübeck – University Hospital S-H, Campus Lübeck, Germany
| | - Rosa Autorino
- Department of Radiation Oncology – Gemelli-ART, Catholic University, Italy
| | | | - Jose Luis Guinot
- Department of Radiation Oncology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain
| | - Guido Hildebrand
- University Hospital Radiotherapy Department, University of Rostock, Germany
| | - Bengt Johansson
- Department of Oncology, Orebro University Hospital and Orebro University, Sweden
| | | | - Jens E. Meyer
- Head & Neck Surgery Department, AK St. George Hospital, Hamburg, Germany
| | | | | | | | - Nicola Dinapoli
- Department of Radiation Oncology – Gemelli-ART, Catholic University, Italy
| | - Vito Lanzotti
- Software programmer manager; KBO-Labs – Gemelli-ART, Catholic University, Italy
| | - Andrea Damiani
- Mathematics; KBO-Labs – Gemelli-ART, Catholic University, Italy
| | - Tamer Soror
- Interdisciplinary Brachytherapy Unit, University of Lübeck – University Hospital S-H, Campus Lübeck, Germany
| | - Vincenzo Valentini
- Department of Radiation Oncology – Gemelli-ART, Catholic University, Italy
| |
Collapse
|
34
|
Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters. Radiother Oncol 2016; 119:501-4. [PMID: 27156652 DOI: 10.1016/j.radonc.2016.04.029] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Revised: 03/30/2016] [Accepted: 04/16/2016] [Indexed: 01/02/2023]
Abstract
PURPOSE/OBJECTIVE The aim of this study is to predict early distant failure in early stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) using clinical parameters by machine learning algorithms. MATERIALS/METHODS The dataset used in this work includes 81 early stage NSCLC patients with at least 6months of follow-up who underwent SBRT between 2006 and 2012 at a single institution. The clinical parameters (n=18) for each patient include demographic parameters, tumor characteristics, treatment fraction schemes, and pretreatment medications. Three predictive models were constructed based on different machine learning algorithms: (1) artificial neural network (ANN), (2) logistic regression (LR) and (3) support vector machine (SVM). Furthermore, to select an optimal clinical parameter set for the model construction, three strategies were adopted: (1) clonal selection algorithm (CSA) based selection strategy; (2) sequential forward selection (SFS) method; and (3) statistical analysis (SA) based strategy. 5-cross-validation is used to validate the performance of each predictive model. The accuracy was assessed by area under the receiver operating characteristic (ROC) curve (AUC), sensitivity and specificity of the system was also evaluated. RESULTS The AUCs for ANN, LR and SVM were 0.75, 0.73, and 0.80, respectively. The sensitivity values for ANN, LR and SVM were 71.2%, 72.9% and 83.1%, while the specificity values for ANN, LR and SVM were 59.1%, 63.6% and 63.6%, respectively. Meanwhile, the CSA based strategy outperformed SFS and SA in terms of AUC, sensitivity and specificity. CONCLUSIONS Based on clinical parameters, the SVM with the CSA optimal parameter set selection strategy achieves better performance than other strategies for predicting distant failure in lung SBRT patients.
Collapse
|
35
|
Nyholm T, Olsson C, Agrup M, Björk P, Björk-Eriksson T, Gagliardi G, Grinaker H, Gunnlaugsson A, Gustafsson A, Gustafsson M, Johansson B, Johnsson S, Karlsson M, Kristensen I, Nilsson P, Nyström L, Onjukka E, Reizenstein J, Skönevik J, Söderström K, Valdman A, Zackrisson B, Montelius A. A national approach for automated collection of standardized and population-based radiation therapy data in Sweden. Radiother Oncol 2016; 119:344-50. [DOI: 10.1016/j.radonc.2016.04.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Revised: 03/30/2016] [Accepted: 04/02/2016] [Indexed: 10/21/2022]
|
36
|
Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, Richter C, Zips D, Bortfeld T. Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016; 16:234-49. [PMID: 27009394 DOI: 10.1038/nrc.2016.18] [Citation(s) in RCA: 525] [Impact Index Per Article: 65.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Technological advances and clinical research over the past few decades have given radiation oncologists the capability to personalize treatments for accurate delivery of radiation dose based on clinical parameters and anatomical information. Eradication of gross and microscopic tumours with preservation of health-related quality of life can be achieved in many patients. Two major strategies, acting synergistically, will enable further widening of the therapeutic window of radiation oncology in the era of precision medicine: technology-driven improvement of treatment conformity, including advanced image guidance and particle therapy, and novel biological concepts for personalized treatment, including biomarker-guided prescription, combined treatment modalities and adaptation of treatment during its course.
Collapse
Affiliation(s)
- Michael Baumann
- Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden
- OncoRay - National Center for Radiation Research in Oncology (NCRO), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstrasse 74, 01307 Dresden
- National Center for Tumor Diseases (NCT), Fetscherstrasse 74, 01307 Dresden
- German Cancer Consortium (DKTK) Dresden, Germany
- German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiation Oncology, Bautzner Landstrasse 400, 01328 Dresden, Germany
| | - Mechthild Krause
- Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden
- OncoRay - National Center for Radiation Research in Oncology (NCRO), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstrasse 74, 01307 Dresden
- National Center for Tumor Diseases (NCT), Fetscherstrasse 74, 01307 Dresden
- German Cancer Consortium (DKTK) Dresden, Germany
- German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiation Oncology, Bautzner Landstrasse 400, 01328 Dresden, Germany
| | - Jens Overgaard
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
| | - Jürgen Debus
- German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
- Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
- National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg
- Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Im Neuenheimer Feld 400, 69120 Heidelberg
- German Cancer Consortium (DKTK) Heidelberg, Germany
| | - Søren M Bentzen
- Department of Epidemiology and Public Health and Greenebaum Cancer Center, University of Maryland School of Medicine, 22 S Greene Street S9a03, Baltimore, Maryland 21201, USA
| | - Juliane Daartz
- Department of Radiation Oncology, Physics Division, Massachusetts General Hospital and Harvard Medical School, 1000 Blossom Street Cox 362, Boston, Massachusetts 02114, USA
| | - Christian Richter
- Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden
- OncoRay - National Center for Radiation Research in Oncology (NCRO), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstrasse 74, 01307 Dresden
- National Center for Tumor Diseases (NCT), Fetscherstrasse 74, 01307 Dresden
- German Cancer Consortium (DKTK) Dresden, Germany
- German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Daniel Zips
- German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
- German Cancer Consortium Tübingen, Postfach 2669, 72016 Tübingen
- Department of Radiation Oncology, Faculty of Medicine and University Hospital Tübingen, Eberhard Karls Universität Tübingen, Hoppe-Seyler-Strasse 3, 72016 Tübingen, Germany
| | - Thomas Bortfeld
- Department of Radiation Oncology, Physics Division, Massachusetts General Hospital and Harvard Medical School, 1000 Blossom Street Cox 362, Boston, Massachusetts 02114, USA
| |
Collapse
|
37
|
Jeanquartier F, Jean-Quartier C, Schreck T, Cemernek D, Holzinger A. Integrating Open Data on Cancer in Support to Tumor Growth Analysis. INFORMATION TECHNOLOGY IN BIO- AND MEDICAL INFORMATICS 2016. [DOI: 10.1007/978-3-319-43949-5_4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
38
|
McNutt TR, Moore KL, Quon H. Needs and Challenges for Big Data in Radiation Oncology. Int J Radiat Oncol Biol Phys 2015; 95:909-915. [PMID: 27302506 DOI: 10.1016/j.ijrobp.2015.11.032] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Revised: 11/13/2015] [Accepted: 11/20/2015] [Indexed: 01/15/2023]
Affiliation(s)
- Todd R McNutt
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland.
| | - Kevin L Moore
- Department of Radiation Oncology, University of California - San Diego, La Jolla, California
| | - Harry Quon
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland
| |
Collapse
|
39
|
De Bari B, Vallati M, Gatta R, Simeone C, Girelli G, Ricardi U, Meattini I, Gabriele P, Bellavita R, Krengli M, Cafaro I, Cagna E, Bunkheila F, Borghesi S, Signor M, Di Marco A, Bertoni F, Stefanacci M, Pasinetti N, Buglione M, Magrini SM. Could machine learning improve the prediction of pelvic nodal status of prostate cancer patients? Preliminary results of a pilot study. Cancer Invest 2015; 33:232-40. [PMID: 25950849 DOI: 10.3109/07357907.2015.1024317] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We tested and compared performances of Roach formula, Partin tables and of three Machine Learning (ML) based algorithms based on decision trees in identifying N+ prostate cancer (PC). 1,555 cN0 and 50 cN+ PC were analyzed. Results were also verified on an independent population of 204 operated cN0 patients, with a known pN status (187 pN0, 17 pN1 patients). ML performed better, also when tested on the surgical population, with accuracy, specificity, and sensitivity ranging between 48-86%, 35-91%, and 17-79%, respectively. ML potentially allows better prediction of the nodal status of PC, potentially allowing a better tailoring of pelvic irradiation.
Collapse
Affiliation(s)
- B De Bari
- 1Istituto del Radio "O. Alberti", Radiotherapy Department, Spedali Civili di Brescia and University of Brescia, Brescia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Niezink AG, Dollekamp NJ, Elzinga HJ, Borger D, Boer EJ, Ubbels JF, Woltman-van Iersel M, van der Leest AH, Beijert M, Groen HJ, Kraan J, Hiltermann TJ, van der Wekken AJ, van Putten JW, Rutgers SR, Pieterman RM, de Hosson SM, Roenhorst AW, Langendijk JA, Widder J. An instrument dedicated for modelling of pulmonary radiotherapy. Radiother Oncol 2015; 115:3-8. [DOI: 10.1016/j.radonc.2015.03.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 03/06/2015] [Accepted: 03/15/2015] [Indexed: 12/25/2022]
|
41
|
Information science ontologies and metaphysics: In regard to an umbrella protocol for standardized data collection in rectal cancer by Meldolesi et al. Radiother Oncol 2015; 114:131. [DOI: 10.1016/j.radonc.2014.08.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Accepted: 08/31/2014] [Indexed: 11/19/2022]
|
42
|
Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasets. Radiother Oncol 2014; 113:303-9. [PMID: 25458128 PMCID: PMC4648243 DOI: 10.1016/j.radonc.2014.10.001] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Revised: 10/01/2014] [Accepted: 10/02/2014] [Indexed: 12/25/2022]
Abstract
Disconnected cancer research data management and lack of information exchange about planned and ongoing research are complicating the utilisation of internationally collected medical information for improving cancer patient care. Rapidly collecting/pooling data can accelerate translational research in radiation therapy and oncology. The exchange of study data is one of the fundamental principles behind data aggregation and data mining. The possibilities of reproducing the original study results, performing further analyses on existing research data to generate new hypotheses or developing computational models to support medical decisions (e.g. risk/benefit analysis of treatment options) represent just a fraction of the potential benefits of medical data-pooling. Distributed machine learning and knowledge exchange from federated databases can be considered as one beyond other attractive approaches for knowledge generation within “Big Data”. Data interoperability between research institutions should be the major concern behind a wider collaboration. Information captured in electronic patient records (EPRs) and study case report forms (eCRFs), linked together with medical imaging and treatment planning data, are deemed to be fundamental elements for large multi-centre studies in the field of radiation therapy and oncology. To fully utilise the captured medical information, the study data have to be more than just an electronic version of a traditional (un-modifiable) paper CRF. Challenges that have to be addressed are data interoperability, utilisation of standards, data quality and privacy concerns, data ownership, rights to publish, data pooling architecture and storage. This paper discusses a framework for conceptual packages of ideas focused on a strategic development for international research data exchange in the field of radiation therapy and oncology.
Collapse
|
43
|
Duchesne GM, Grand M, Kron T, Haworth A, Corry J, Jackson M, Ng M, Besuijen D, Carter HE, Martin A, Schofield D, Gebski V, Torony J, Kovacev O, Amin R, Burmeister B. Trans Tasman Radiation Oncology Group: Development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework. J Med Imaging Radiat Oncol 2014; 59:363-70. [DOI: 10.1111/1754-9485.12255] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2014] [Accepted: 09/16/2014] [Indexed: 12/25/2022]
Affiliation(s)
- Gillian M Duchesne
- Peter MacCallum Cancer Centre; Melbourne Victoria Australia
- University of Melbourne; Melbourne Victoria Australia
- Monash University; Melbourne Victoria Australia
| | - Mel Grand
- Trans Tasman Radiation Oncology Group; Newcastle New South Wales Australia
| | - Tomas Kron
- Peter MacCallum Cancer Centre; Melbourne Victoria Australia
- Monash University; Melbourne Victoria Australia
- RMIT University; Melbourne Victoria Australia
| | - Annette Haworth
- Peter MacCallum Cancer Centre; Melbourne Victoria Australia
- University of Melbourne; Melbourne Victoria Australia
| | - June Corry
- Peter MacCallum Cancer Centre; Melbourne Victoria Australia
- University of Melbourne; Melbourne Victoria Australia
| | - Michael Jackson
- University of New South Wales; Sydney New South Wales Australia
| | - Michael Ng
- Radiation Oncology Victoria; Melbourne Victoria Australia
| | - Deidre Besuijen
- Trans Tasman Radiation Oncology Group; Newcastle New South Wales Australia
| | - Hannah E Carter
- NHMRC Clinical Trials Centre; University of Sydney; Sydney New South Wales Australia
| | - Andrew Martin
- NHMRC Clinical Trials Centre; University of Sydney; Sydney New South Wales Australia
| | - Deborah Schofield
- NHMRC Clinical Trials Centre; University of Sydney; Sydney New South Wales Australia
- School of Public Health; University of Sydney; Sydney New South Wales Australia
| | - Val Gebski
- NHMRC Clinical Trials Centre; University of Sydney; Sydney New South Wales Australia
| | - Joan Torony
- Trans Tasman Radiation Oncology Group; Newcastle New South Wales Australia
| | - Olga Kovacev
- Trans Tasman Radiation Oncology Group; Newcastle New South Wales Australia
| | - Rowena Amin
- Health and Training Institute; Sydney New South Wales Australia
| | - Bryan Burmeister
- Princess Alexandra Hospital; University of Queensland; Brisbane Queensland Australia
| |
Collapse
|
44
|
Meldolesi E, van Soest J, Alitto AR, Autorino R, Dinapoli N, Dekker A, Gambacorta MA, Gatta R, Tagliaferri L, Damiani A, Valentini V. VATE: VAlidation of high TEchnology based on large database analysis by learning machine. COLORECTAL CANCER 2014. [DOI: 10.2217/crc.14.34] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
SUMMARY The interaction between implementation of new technologies and different outcomes can allow a broad range of researches to be expanded. The purpose of this paper is to introduce the VAlidation of high TEchnology based on large database analysis by learning machine (VATE) project that aims to combine new technologies with outcomes related to rectal cancer in terms of tumor control and normal tissue sparing. Using automated computer bots and the knowledge for screening data it is possible to identify the factors that can mostly influence those outcomes. Population-based observational studies resulting from the linkage of different datasets will be conducted in order to develop predictive models that allow physicians to share decision with patients into a wider concept of tailored treatment.
Collapse
Affiliation(s)
- Elisa Meldolesi
- Department of Radiation Oncology, Sacred Heart University, Rome, Italy
| | - Johan van Soest
- Department of Radiation Oncology (MAASTRO) GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
| | - Anna Rita Alitto
- Department of Radiation Oncology, Sacred Heart University, Rome, Italy
| | - Rosa Autorino
- Department of Radiation Oncology, Sacred Heart University, Rome, Italy
| | - Nicola Dinapoli
- Department of Radiation Oncology, Sacred Heart University, Rome, Italy
| | - Andre Dekker
- Department of Radiation Oncology (MAASTRO) GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
| | | | - Roberto Gatta
- Department of Radiation Oncology, Sacred Heart University, Rome, Italy
| | - Luca Tagliaferri
- Department of Radiation Oncology, Sacred Heart University, Rome, Italy
| | - Andrea Damiani
- Department of Radiation Oncology, Sacred Heart University, Rome, Italy
| | | |
Collapse
|
45
|
Meldolesi E, van Soest J, Dinapoli N, Dekker A, Damiani A, Gambacorta MA, Valentini V. An umbrella protocol for standardized data collection (SDC) in rectal cancer: a prospective uniform naming and procedure convention to support personalized medicine. Radiother Oncol 2014; 112:59-62. [PMID: 24853366 DOI: 10.1016/j.radonc.2014.04.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 04/17/2014] [Accepted: 04/18/2014] [Indexed: 01/01/2023]
Abstract
Predictive models allow treating physicians to deliver tailored treatment moving from prescription by consensus to prescription by numbers. The main features of an umbrella protocol for standardizing data and procedures to create a consistent dataset useful to obtain a trustful analysis for a Decision Support System for rectal cancer are reported.
Collapse
Affiliation(s)
- Elisa Meldolesi
- Sacred Heart University, Radiotherapy Department, Rome, Italy.
| | - Johan van Soest
- Maastricht University Medical Centre+, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, The Netherlands
| | - Nicola Dinapoli
- Sacred Heart University, Radiotherapy Department, Rome, Italy
| | - Andre Dekker
- Maastricht University Medical Centre+, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, The Netherlands
| | - Andrea Damiani
- Sacred Heart University, Radiotherapy Department, Rome, Italy
| | | | | |
Collapse
|
46
|
Gulliford S. Response to "Comment on 'Future radiotherapy practice will be based on evidence from retrospective interrogation of linked clinical data sources rather than prospective randomized controlled clinical trials'" [Med. Phys. 41(3), 030601 (3pp.) (2014)]. Med Phys 2014; 41:057103. [PMID: 24784412 DOI: 10.1118/1.4871786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Affiliation(s)
- Sarah Gulliford
- Joint Department of Physics, The Institute of Cancer Research and Royal Marsden, NHS Foundation Trust, Downs Road - Sutton, Surrey SM2 5PT United Kingdom
| |
Collapse
|
47
|
Deasy JO, Muren LP. Advancing our quantitative understanding of radiotherapy normal tissue morbidity. Acta Oncol 2014; 53:577-9. [PMID: 24724930 DOI: 10.3109/0284186x.2014.907055] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Joseph O Deasy
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center , New York , USA
| | | |
Collapse
|
48
|
Roelofs E, Persoon L, Nijsten S, Wiessler W, Dekker A, Lambin P. Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. Radiother Oncol 2013; 108:174-9. [PMID: 23394741 DOI: 10.1016/j.radonc.2012.09.019] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2011] [Revised: 09/10/2012] [Accepted: 09/29/2012] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Collecting trial data in a medical environment is at present mostly performed manually and therefore time-consuming, prone to errors and often incomplete with the complex data considered. Faster and more accurate methods are needed to improve the data quality and to shorten data collection times where information is often scattered over multiple data sources. The purpose of this study is to investigate the possible benefit of modern data warehouse technology in the radiation oncology field. MATERIAL AND METHODS In this study, a Computer Aided Theragnostics (CAT) data warehouse combined with automated tools for feature extraction was benchmarked against the regular manual data-collection processes. Two sets of clinical parameters were compiled for non-small cell lung cancer (NSCLC) and rectal cancer, using 27 patients per disease. Data collection times and inconsistencies were compared between the manual and the automated extraction method. RESULTS The average time per case to collect the NSCLC data manually was 10.4 ± 2.1 min and 4.3 ± 1.1 min when using the automated method (p<0.001). For rectal cancer, these times were 13.5 ± 4.1 and 6.8 ± 2.4 min, respectively (p<0.001). In 3.2% of the data collected for NSCLC and 5.3% for rectal cancer, there was a discrepancy between the manual and automated method. CONCLUSIONS Aggregating multiple data sources in a data warehouse combined with tools for extraction of relevant parameters is beneficial for data collection times and offers the ability to improve data quality. The initial investments in digitizing the data are expected to be compensated due to the flexibility of the data analysis. Furthermore, successive investigations can easily select trial candidates and extract new parameters from the existing databases.
Collapse
Affiliation(s)
- Erik Roelofs
- Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Centre (MUMC+), The Netherlands.
| | | | | | | | | | | |
Collapse
|